Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

What this study is about

This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.

Who can join (things the study team will check)

✅ You may be able to join if…

• ECOG 0-3
• Life expectancy > 6 months
• Informed consent and willingness to undergoing serial genetic panel CHIP testing.
• Cohort Specific criteria
  • Cohort A: PRRT completed within 5 years of enrolment
  • Cohort B: PRRT planned to commence within 4 months of enrolment
  • Cohort C: diagnosis of MDS or AML following prior PRRT.

🚫 You may not be able to join if…

• Unwillingness to provide blood sample and follow up as per protocol

Where this trial is running

• Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Who to contact

Rebecca Wong · 416-946-4501 · rebecca.wong@uhn.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06510868.